Table 2.
Summary of the antiviral potency and selectivity of PI4KIII inhibitors.
| Molecule | PIK inhibition (IC50, μM) |
Viral potency in vitro (EC50, μM) |
|||
|---|---|---|---|---|---|
| PI4KIIIα | PI4KIIIβ | Other PIKs | Picornavirus | HCV | |
| PIK93 | 1.1 | 0.019 | Active against some PI3Ks of class I, II and III | 0.14 (PV) | 0.17 (GT 1b replicon) |
| Enviroxime | 1.4 | 0.12 | nd | 0.7 (CVB3), 0.19 (PV1), 0.11 (HRV14) | 0.22 (GT 1b replicon) |
| Cpd 6 (Novartis) | nd | 0.024 | nd | nd | 0.13 (GT 1b replicon) |
| AL-9 | 0.57 | 3.08 | PI3K p110α: 1.1 | nd | 0.29 (GT 1b replicon) |
| Inhibitor A (BI) | 0.45 | nd | nd | nd | 0.3 (GT 1b replicon) |
nd: not determined; GT: genotype; CVB3: coxsackievirus B3; PV1: poliovirus 1; HRV14: human rhinovirus 14; Cpd: compound; BI: Boehringer Ingelheim.